TCGA-BH-A18V-01A-11R-A12D-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.560
- E2F_TARGETS+0.530
- IL6_JAK_STAT3_SIGNALING+0.470
- INTERFERON_GAMMA_RESPONSE+0.430
- INFLAMMATORY_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.410
- TNFA_SIGNALING_VIA_NFKB+0.410
- MITOTIC_SPINDLE+0.380
- MTORC1_SIGNALING+0.370
- INTERFERON_ALPHA_RESPONSE+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- BILE_ACID_METABOLISM-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ADIPOGENESIS-0.260
- ESTROGEN_RESPONSE_LATE-0.230
- XENOBIOTIC_METABOLISM-0.220
- FATTY_ACID_METABOLISM-0.180
- P53_PATHWAY-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
- PEROXISOME-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A1G1-01A-21R-A13Q-07 | — | E | 0.912 |
| 2 | TCGA-A8-A08R-01A-11R-A034-07 | — | E | 0.900 |
| 3 | SAMN03290909 | — | — | 0.887 |
| 4 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.881 |
| 5 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.854 |
| 6 | TCGA-D8-A1JL-01A-11R-A13Q-07 | — | D | 0.848 |
| 7 | GSM5359424 | — | — | 0.838 |
| 8 | BS_84XCR9GG | high-grade glioma | — | 0.838 |
| 9 | TCGA-A2-A0YM-01A-11R-A109-07 | — | E | 0.837 |
| 10 | SRR8943028 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |